Current status of cardiac transplantation

JAMA

Volumn 280, Issue 19, 1998, Pages 1692-1698

  Hunt, Sharon A ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; ARTICLE; ASSISTED CIRCULATION; CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OPPORTUNISTIC INFECTION; ORGAN DONOR; PATIENT SELECTION; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; XENOTRANSPLANTATION;

EID: 0032544952     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.19.1692     Document Type: Article

References (80)

1. Barnard CN. The operation. S Afr Med J. 1967; 30:1271-1274.
2. Lower RR, Shumway NE. Studies of orthotopic homotransplantation of the canine heart. Surg Forum. 1960;11:18-19.
3. Lower RR, Stofer RC, Hurley EJ, Dong E, Cohn RB, Shumway NE. Successful homotransplantation of the canine heart after anoxic preservation for seven hours. Am J Surg. 1962;104:302-306.
4. Dreyfus G, Jebara V, Mihaileanu MD, Carpentier A. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg. 1991;52:1181-1184.
5. Deleuze PH, Benvenuti C, Mazzucotelli MD, et al. Orthotopic cardiac transplants with direct caval anastomosis: is it the optimal procedure? J Thorac Cardiovasc Surg. 1995;109:731-737.
6. Trento A, Czer LSC, Blanche C. Surgical techniques for cardiac transplantation. Semin Thorac Cardiovasc Surg. 1996;8:126-132.
7. Pope SE, Stinson EB, Daughters GT, Schroeder JS, Ingels NV, Alderman EL. Exercise response of the denervated heart in long-term cardiac transplant recipients. Am J Cardiol. 1980;46:213-218.
8. Pflugfelder PW, Purves PD, McKenzie FN, Kostuk WJ. Cardiac dynamics during supine exercise in cyclosporine-treated orthotopic heart transplant recipients: assessment by radionuclide angiography. J Am Coll Cardiol. 1987;10:336-341.
9. Gao SZ, Schroeder JS, Hunt SA, Billingham ME, Valantine HA, Stinson EB. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol. 1989;64:1093-1097.
10. Savin W, Schroeder J, Haskell W. Response of cardiac transplant recipients to static and dynamic exercise: a review. Heart Transplant. 1982;1:72-79.
11. Ehrman J, Keteyian S, Fedel F, Rhoads K, Levine T, Shepard R. Cardiovascular responses of heart transplant recipients to graded exercise testing. J Appl Physiol. 1992;73:260-264.
12. Stevenson L, Sietsema K, Tillisch J, et al. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. Circulation. 1990;81:78-85.
13. Mancini D. Surgically denervated cardiac transplant: rewired or permanently unplugged? Circulation. 1997;96:6-8.
14. Wilson RF, Christensen BV, Oliari MT, Simon A, White CW, Laxson MD. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation. 1991;83: 1210-1220.
15. Burke MN, McGinn AL, Homans DC, Christensen BV, Kubo SH, Wilson RF. Evidence for functional sympathetic reinnervation of left ventricle and coronary arteries after orthotopic cardiac transplantation in humans. Circulation. 1995;91:72-78.
16. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac transplant recipients: evidence of sensory reinnervation after cardiac transplantation. N Engl J Med. 1991;324:1791-1794.
17. Givertz MM, Harley H, Colucci WS. Long-term sequential changes in exercise capacity and chronotropic responsiveness after cardiac transplantation. Circulation. 1997;96:232-237.
18. Hunt SA. 24th Bethesda Conference: Cardiac Transplantation. J Am Coll Cardiol. 1993;22:1-64.
19. Stevenson WG, Stevenson LW, Middlekauf HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417-1423.
20. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The registry of the International Society for Heart and Lung Transplantation: 15th official report - 1998. J Heart Lung Transplant. 1998;17:656-668.
21. Hosenpud JD, Breen TJ, Edwards EB, Daily OP, Hunsicker LG. The effect of transplant center volume on cardiac transplant outcome. JAMA. 1994; 271:1844-1849.
22. Medicare programs: criteria for Medicare coverage of heart transplants. 52 Federal Register 10935-10951 (1987).
23. Krakuer H, Shakar SS, Kaye MP. The relationship of clinical outcomes to status as a Medicare-approved heart transplant center. Transplantation. 1995;59:840-846.
24. Grady KL, Jalowiec A, White-Williams C. Improvement in quality of life in patients with heart failure who undergo transplantation. J Heart Lung Transplant. 1996;15:749-757.
25. Kahan BD. Cyclosporine. N Engl J Med. 1989; 321:1725-1737.
26. Oyer PE, Stinson EB, Jamieson SW, et al. Cyclosporine A in cardiac allografting: a preliminary experience. Transplant Proc. 1983;15:1247-1252.
27. Starnes VA, Oyer PE, Stinson EB, Dein JR, Shumway NE. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation. 1989;80(suppl 3):79-83.
28. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110-1115.
29. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet. 1994;344:423-428.
30. Armitage JM, Kormos RL, Griffith BP, et al. A clinical trial of FK506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc. 1991;23:1149-1152.
31. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 1996;111:1-9.
32. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
33. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-232.
34. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037.
35. Gregory CR, Pratt RE, Huie P, et al. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular smooth muscle proliferation in vitro and in vivo. Transplant Proc. 1993;25:770-771.
36. Gilbert EM, DeWitt CW, Eiswirth CC, et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med. 1987; 82:202-206.
37. Costanzo-Nordin MR, Grusk BB, Silver MA, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation. 1988;78(suppl 3):47-57.
38. Bouchart F, Gundry SR, Van Schaak-Gonzales J, et al. Methotrexate as rescue/adjunctive immunotherapy in infant and adult heart transplantation. J Heart Lung Transplant. 1993;12:427-433.
39. Levin B, Bohannon V, Warvariv V, Bry W, Collins G. Total lymphoid irradiation (TLI) in the cyclosporine era: use of TL1 in resistant cardiac allograft rejection. Transplant Proc. 1989;21:1793-1795.
40. Keogh A, Morgan G, Macdonald P, Spratt P, Mundy J, McCosker C. Total lymphoid irradiation for resistant rejection after heart transplantation: only moderate success medium-term. J Heart Lung Transplant. 1996;15:231-233.
41. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, et al. Successful treatment of heart transplant rejection with photophoresis. Transplantation. 1992;53:808-815.
42. Meiser BM, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation. 1994;57:563-568.
43. Caves PK, Stinson EB, Billingham ME, Shumway NE. Serial transvenous biopsy of the transplanted human heart: improved management of acute rejection episodes. Lancet. 1974;1:822-826.
44. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transplant. 1990;9:587-592.
45. Olsen SL, Eastburn TE, Renlund DG, et al. Trimethoprim sulfamethoxazole prevents Pneumocystis carinii pneumonia in cardiac transplant recipients. J Heart Transplant. 1990;9:20A.
46. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182-1186.
47. Valantine HA. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Transplant Proc. 1995;27(suppl 1):49-57.
48. Gao SZ, Schroeder JS, Alderman EL, et al. Prevalence of accelerated coronary artery disease in heart transplant survivors: comparison of cyclosporine and azathioprine regimens. Circulation. 1989;80(suppl 3):100-105.
49. Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving triple-drug immunosuppressive therapy. Circulation. 1989;80(suppl 3):111-115.
50. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987; 76:827-834.
51. Park JW, Merz M, Braun P, Vermeltfoort M. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant. 1996;15:572-579.
52. Rickenbacker PR, Kemna MS, Pinto FJ, et al. Coronary artery intimal thickening in the transplanted heart. Transplantation. 1996;61:46-53.
53. Valantine H, Rickenbacker P, Kemna MS, et al. Metabolic abnormalities characteristic of syndrome X predict long-term outcome in heart transplant patients. J Heart Lung Transplant. 1995;14(pt2):S58.
54. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566.
55. McDonald K, Rector TS, Braunlin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359-362.
56. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol 1996;28:673-679.
57. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams JH. Cardiac rejection: an undefined conundrum. Transplantation. 1991;52:389-398.
58. Callard P, Bedrossian J, Idatte JM, et al. The arterial lesions in the cause of renal allograft rejection. Adv Nephrol. 1975;5:333-353.
59. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RAF. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology. 1987;7:476-483.
60. Griffith BP, Paradis IL, Zeevi A, et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg. 1988;208:371-378.
61. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary angiographic findings. J Am Coll Cardiol. 1988;12:340-344.
62. St Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of "angiographically silent" intimal thickening. Circulation. 1992;85:979-987.
63. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant. 1995;14:632-639.
64. Gao SZ, Schroeder JS, Hunt SA, Billingham ME, Valantine HA, Stinson EB. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol. 1989;64:1093-1097.
65. Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.
66. Halle AA, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26:120-128.
67. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative diseases. N Engl J Med. 1989;321:1080-1085.
68. Hanto DW, Frizzera G, Gail-Peczalska KJ, et al. The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc. 1981;13:756-760.
69. Hanto DW. Classification of Epstein-Barr virus-associated post-transplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med. 1995;46:381-394.
70. Starzl TE, Porter FA, Iwatsuki S, et al. Reversibility of lymphoma and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984;1:583-687.
71. Kirk AD, Harlan DM, Armstrong NN, et al. CT-DLA4-Ig and anti-CD40 prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997; 94:8789-8794.
72. DeVries WC, Anderson JL, Joyce LD, et al. Clinical use of the total artificial heart. N Engl J Med. 1984;310:273-278.
73. Griffith BP, Hardesty RL, Kormos RL, et al. Temporary use of the Jarvik-7 total artificial heart before transplantation. N Engl J Med. 1987;316:130-134.
74. Portner PM, Oyer PE, Pennington DG, et al. Implantable left ventricular assist system: bridge to transplant and the future. Ann Thorac Surg. 1989; 47:142-150.
75. Kormos RL, Murali S, Dew MA, et al. Chronic mechanical circulatory support: rehabilitation, low morbidity, and superior survival. Ann Thorac Surg. 1994;57:51-58.
76. Platt JL. Approaching the clinical application of xenotransplantation. Am J Med Sci. 1997;313:315-321.
77. McCurry KR, Kooyman DL, Alvarado CG. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med. 1995;1:423-427.
78. Thompson C. Humanized pigs' hearts boost xenotransplantation. Lancet. 1995;346:766.
79. Chapman LE, Folks TM, Salomon D, Patterson AP, Eggerman TE, Noguchi PD. Xenotransplantation and xenogeneic infections. N Engl J Med. 1995; 333:1498-1501.
80. Bach FH, Fishman JA, Daniels N, et al. Uncertainty in xenotransplantation: individual benefit vs collective risk. Nat Med. 1998;4:141-144.